About emergent biosolutions inc. - EBS
Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.
EBS At a Glance
Emergent BioSolutions, Inc.
300 Professional Drive
Gaithersburg, Maryland 20879
| Phone | 1-240-631-3200 | Revenue | 742.90M | |
| Industry | Pharmaceuticals: Major | Net Income | 52.60M | |
| Sector | Health Technology | Employees | 900 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
EBS Valuation
| P/E Current | 8.677 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 13.323 |
| Price to Sales Ratio | 0.943 |
| Price to Book Ratio | 1.232 |
| Price to Cash Flow Ratio | 4.11 |
| Enterprise Value to EBITDA | 5.158 |
| Enterprise Value to Sales | 1.448 |
| Total Debt to Enterprise Value | 0.543 |
EBS Efficiency
| Revenue/Employee | 825,444.444 |
| Income Per Employee | 58,444.444 |
| Receivables Turnover | 8.823 |
| Total Asset Turnover | 0.544 |
EBS Liquidity
| Current Ratio | 5.011 |
| Quick Ratio | 2.414 |
| Cash Ratio | 1.582 |
EBS Profitability
| Gross Margin | 47.193 |
| Operating Margin | 14.834 |
| Pretax Margin | 11.146 |
| Net Margin | 7.08 |
| Return on Assets | 3.855 |
| Return on Equity | 10.463 |
| Return on Total Capital | 4.755 |
| Return on Invested Capital | 4.655 |
EBS Capital Structure
| Total Debt to Total Equity | 111.692 |
| Total Debt to Total Capital | 52.761 |
| Total Debt to Total Assets | 43.821 |
| Long-Term Debt to Equity | 111.232 |
| Long-Term Debt to Total Capital | 52.545 |
Emergent Biosolutions Inc. in the News
J&J COVID-19 vaccine manufacturing halted at US plant that had contamination issue
Production of Johnson & Johnson’s (JNJ.N) COVID-19 vaccine at a U.S. manufacturing plant was halted by the U.S. Food and Drug Administration while the agency investigates an error that led to millions of doses being ruined last month.